All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Journal of Clinical Psychiatry and Neuroscience

Sign up for email alert when new content gets added: Sign up

Tammi McGill-Carter
Neuropsychiatrist, Private practice, USA, Email: [email protected]

This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (, which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact [email protected]

The global CNS therapeutic market is expected to reach USD 128.9 billion by 2025, according to a new report by Grand View Research, Inc. Rising prevalence of mental illnesses and increasing awareness regarding psychiatric disorders are driving market growth. In addition, expanding geriatric population and rising prevalence of lifestyle-associated CNS disorders are increasing global demand for CNS therapeutics.

Further Key Findings from the Report Suggest:

• Global mental health therapeutics revenue accounted for 48% share in 2016 and is expected to grow at a significant rate from 2016 to 2025

• Global demand for the treatment of Parkinson’s and Alzheimer’s diseases is anticipated to witness extensive growth over the next 9 years

• The industry in Asia Pacific is expected to report fastest growth over the forecast period owing to various developments across major economies of the region, especially in the mental health sector.

• Key players including Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Biogen, Inc.; Johnson & Johnson Services, Inc.; Eli Lilly and Company; and Novartis AG led the global CNS disease treatment market by capturing a majority share.

The central nervous system is a complex network of thread-like nerves and cells that carry messages to and from the brain and spinal cord to various parts of the body including the sensory organs, arms, hands, legs, and feet. A neurosurgeon is a physician who specializes in the diagnosis and surgical treatment of disorders of the central and peripheral nervous system including congenital anomalies, trauma, tumours, vascular disorders, infections of the brain or spine, stroke, or degenerative diseases of the spine.

The global central nervous system drugs market was valued at around $71 billion in 2017 and is expected to reach around $82 billion in 2020. North America was the largest region in the central nervous system drugs market in 2017, accounting for nearly 40% market share. The USA was the largest country in the market in 2017, accounting for nearly 30% market share and is anticipated to grow at a CAGR of 5.9% during the forecast period. Advancements in diagnostics, therapeutics, and drug discovery techniques are primarily driving the growth of the market. Moreover, rising demand for effective therapeutic options are motivating major pharmaceutical companies to invest on R&D for the same, thus creating future growth opportunities. In addition, growing geriatric population prone to various CNS diseases including Alzheimer’s and schizophrenia is expected to fuel the growth. Furthermore, the number of patients is expected to increase with increasing prevalence of CNS diseases associated with sedentary lifestyle and chronic mental disorders.

The delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders. Drugs may be administered directly into the CNS or administered systematically (e.g., by intravenous injection) for targeted action in the CNS. The major challenge to CNS drug delivery is the blood-brain barrier (BBB), which limits the access of drugs to the brain substance.

The method of delivery of a drug to the CNS has an impact on the drug's commercial potential. The market for CNS drug delivery technologies is directly linked to the CNS drug market. Values are calculated for the total CNS market and the share of drug delivery technologies. Starting with the market values for the year 2017, projections are made to the years 2022 and 2027.


The central nervous system (CNS) is a vital part of the brain and spinal cord nervous system. This incorporates the information received, then manages and monitors all aspects of the body's activities. CNS conditions such as neurodegenerative diseases, autoimmune and inflammatory diseases, genetic disorders, cancers and others, however, impair the structure and function.

The growth of the CNS therapeutic market is driven primarily by advances in techniques for diagnosis, therapy, and drug discovery. Increasing demand for effective therapeutic options for CNS also encourages major pharmaceutical firms to invest in R&D, creating opportunities for future growth. In addition, increased awareness of psychiatric disorders, increased incidence of mental disorders

The rate of serious psychological distress among adolescents and young adults has been on a rise since past few years, which further fuels the demand for CNS therapeutics across the globe. However, stringent & protracted drug approval procedures and soaring prices of advanced treatments are projected to restrain the growth of the CNS therapeutics market. On the contrary, lucrative opportunities industries

The pharmaceutical market for the central nervous system consists of sales of central nervous system drugs and related services by companies (organizations, sole traders and partnerships) that manufacture central nervous system drugs to treat disorders of the brain and spinal cord. This industry includes establishments that manufacture medicines for the nervous system, analgesic pain relief, anti-Parkinson medicines for Parkinson's disease,

The demand for drugs in the central nervous system expected to reach a value of approximately $103.23 billion by 2022, rising steadily over the forecast period at a CAGR of 3.7 percent. Growth in the pharmaceutical market for the Central Nervous System is due to steps taken by the U.S. FDA (Food and Drug Administration) and EMA (European Medicines Agency) to provide Central Nervous with different regulatory designations

Recommended Conferences

3rd Annual Congress on Psychiatry

London, United Kingdom